Enzo Biochem, Inc. (Enzo) is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company also operates a clinical laboratory that offers and provides diagnostic medical testing services to the health care community in the New York Metropolitan and New Jersey areas. The Company operates in three segments: Enzo Life Sciences, Enzo Therapeutics and Enzo Clinical Labs. On May 8, 2008, Enzo Life Sciences, Inc., a wholly owned subsidiary of the Company, acquired all of the United States-based assets of Biomol International, LP (Biomol) and its wholly owned United Kingdom subsidiary, Affinity Limited. ENZO® - A Brand of Enzo Life Sciences, Inc. Innovative Labeling and Detection™
Enzo® is a recognized leader in labeling and detection technologies across research and diagnostic markets. A strong portfolio of labeling probes and dyes provides life science environments tools for target identification/validation and high content analysis via gene expression analysis, nucleic acid detection, protein biochemistry and detection, and molecular and cellular biology.
![Enzolifesciences/[pSer<sup>8</sup>]GFAP monoclonal antibody (YC10)/ADI-NBA-115-D/50µg](images/201711/1511479559171067869.jpg)
